National Institute of Mental Health

Deliberate AI focuses on advancing mental health care through its development of multimodal artificial intelligence technologies. The company specializes in regulatory-grade measurement tools that enhance diagnostics and monitoring for behavioral and mental health applications. Their platform employs AI algorithms to deliver objective assessments and insights, supporting clinicians, physicians, and researchers in mental and neurological healthcare and clinical trials. By enabling precision therapy and integrating ambient clinical intelligence, Deliberate AI aims to improve the quality of care and outcomes for patients undergoing mental health treatment.

PsychoGenics is a research company offering preclinical testing and research services.

Rumi Scientific is a research-oriented company focused on developing innovative medications and treatments for genetic disorders affecting the central nervous system, particularly Huntington's Disease. The company utilizes a proprietary human organoid platform that simulates human development in vitro, integrating gene editing techniques with multi-cellular self-organization to create defined diseased embryonic tissues. This advanced platform facilitates drug discovery and high-throughput screening, leveraging artificial intelligence to identify potential treatments. By emphasizing synthetic human embryology in both healthy and diseased contexts, Rumi Scientific aims to advance therapeutic options for numerous genetic conditions that currently lack effective cures. The company's approach combines single-cell, time-lapse imaging with customized analytic tools, resulting in a more efficient and cost-effective drug development process that enhances treatment success rates and outcomes for patients.

Innerworld is a mental health community that operates within the metaverse, offering a virtual reality platform focused on cognitive-behavioral therapy. This innovative platform aims to provide a safe and supportive environment where individuals can build meaningful relationships while learning evidence-based techniques to address real-world mental health challenges. By facilitating the treatment and understanding of mental health disorders, Innerworld enables users to acquire essential skills for emotional regulation and overall well-being.

PsychoGenics is a research company offering preclinical testing and research services.

Arcade Therapeutics is focused on enhancing mental health through innovative mobile gaming solutions. Utilizing groundbreaking neuroscientific research, the company has developed a digital therapeutics platform that offers game-like cognitive training designed to modify attention patterns contributing to anxiety and stress. This platform employs an attention bias modification approach, helping users manage disruptive habits that sustain their mental health challenges. Additionally, Arcade Therapeutics incorporates artificial intelligence to gather data and provide risk stratification, allowing for a scientific approach to mental wellness. By making these therapeutic interventions accessible and engaging, the company aims to improve health outcomes for individuals dealing with behavioral and mental health issues.

Lyssn is a mental health care platform that utilizes artificial intelligence technology to enhance training and quality assurance for mental health professionals. The platform enables users to record and share psychotherapy conversations, transforming these recordings into data through comprehensive transcripts and metrics. This functionality provides valuable feedback to both trainees and experienced counselors, allowing them to assess the emotional states and behaviors of patients effectively. By analyzing health outcomes, Lyssn supports healthcare professionals in improving their practices and fostering better patient care.

Soterix Medical develops devices and accessories based on neuromodulation and brain stimulation technologies. The company was founded by Abhishek Datta and is based in New York, the United States.

Meru Health, Inc. is a digital healthcare company that focuses on improving the lives of individuals dealing with mental health issues such as depression, anxiety, and stress. Founded in 2015 and based in San Mateo, California, with additional offices in Palo Alto and Helsinki, Meru Health develops a mobile application that connects users to licensed therapists through a structured 12-week program. This program combines continuous remote clinician support with at-home lessons, cognitive behavioral therapy, and coaching on sleep and nutrition. By offering clinically proven and cost-effective digital therapeutic solutions, Meru Health aims to empower patients and enhance the efficiency of mental health treatment.

Imaginostics specializes in developing advanced diagnostic tools aimed at enhancing precision medicine for clinicians and drug developers. Utilizing proprietary MRI physics-based technology, the company offers significantly improved vascular imaging and quantitative assessments of vascular structure, function, and leakage. This innovative approach not only produces images ten times better than traditional methods but is also compatible with existing MRI scanners and utilizes a safe iron supplement for contrast instead of toxic gadolinium. Imaginostics provides biomarker solutions through collaborations with contract research organizations and engages in pre-clinical and clinical research across various focus areas, working alongside leading researchers at prestigious institutions. The company's noninvasive imaging technology is designed to aid in the diagnosis of neurological disorders, facilitate safe vascular visualization for renal patients, and support acute diagnostics for conditions like traumatic brain injury or stroke, ultimately enabling hospitals to monitor disease progression and evaluate drug effects efficiently.

Mightier is a gaming platform and family program scientifically-proven to help kids regulate their emotions. It is a bioresponsive program that harnesses the mind-body connection to build emotional regulation in its players. Its program of bioresponsive video games, developed at Boston Children's Hospital and Harvard Medical School, aims to help children with behavioral and emotional challenges learn how to harness emotions in daily life. Mightier was founded in 2016 and is headquartered in Boston, Massachusetts.

Camino Pharma is a San Diego-based startup company focused on discovering and developing first-in-class therapies for patients suffering from cancer and CNS disorders. They target signaling proteins based on emerging biological concepts and discover novel mechanisms for modulating these targets with small molecule drugs. Their leadership team has proven expertise in the relevant target biology, as well as extensive experience in drug discovery and development.

Backyard Brains specializes in providing accessible neuroscience tools and experiment kits designed for individuals of all ages to explore brain science. The company offers affordable kits that facilitate hands-on learning about electrophysiology, allowing users—from schoolchildren to graduate students—to conduct experiments similar to those performed by professional neuroscientists. Their products enable participants to record and analyze electrical activity from various biological systems, including motor units and the brain itself. By simplifying complex neuroscience concepts, Backyard Brains empowers everyone to engage in the discovery of how the brain communicates, enhancing understanding of its role in senses, memories, and emotions.

FIRMM is a software-based biofeedback solution, called Framewise Integrated Real-Time MRI Monitoring (FIRMM), for acquiring better brain MR exams.

Cogito is a technology company focused on improving the emotional intelligence of phone professionals through the use of artificial intelligence and machine learning. Its innovative software analyzes various behavioral signals during voice interactions, offering real-time coaching to agents and assessing customer experience throughout each call. This system is designed to strengthen human connections, helping enterprises enhance relationships with customers, boost sales performance, and improve the overall quality of service provided. By leveraging behavioral science, Cogito aims to transform the way organizations engage with their clientele.

McLean Hospital, established in 1811, is a comprehensive mental health care facility located in Massachusetts and affiliated with Harvard Medical School. It specializes in providing a wide range of high-quality mental health services aimed at improving the lives of individuals and families affected by psychiatric illnesses. With a dedicated staff of over 1,900 professionals, McLean Hospital offers compassionate care and support for patients. As the largest psychiatric teaching facility of Harvard Medical School, it plays a significant role in training future mental health professionals while also engaging in ongoing research to advance the field of psychiatry. The hospital's commitment to mental health care is reflected in its focus on effective, evidence-based treatment and its efforts to foster community outreach and support.

The Brown School offers excellence in social work, public health and social policy graduate education. The school's community of students and scholars dig in every day to work towards social, health, racial and economic equity so that all people can live and thrive. The future of social work and public health depends on leading evidence-based research; moving that research into practice; and preparing students to excel in their work. Brown School faculty excel in these pursuits, and the work they are doing is vital for creating change.

Backyard Brains specializes in providing accessible neuroscience tools and experiment kits designed for individuals of all ages to explore brain science. The company offers affordable kits that facilitate hands-on learning about electrophysiology, allowing users—from schoolchildren to graduate students—to conduct experiments similar to those performed by professional neuroscientists. Their products enable participants to record and analyze electrical activity from various biological systems, including motor units and the brain itself. By simplifying complex neuroscience concepts, Backyard Brains empowers everyone to engage in the discovery of how the brain communicates, enhancing understanding of its role in senses, memories, and emotions.

DFusion is a science-based behavioral health research and development company that focuses on promoting behavior change for health, prevention, and adherence. Leveraging evidence-based models and learning theories, DFusion creates innovative applications of both modern and traditional technologies aimed at enhancing health outcomes. The company develops smartphone, tablet, and web applications that are informed by behavioral research, ensuring an optimal user experience. Additionally, DFusion offers consultation services and professional development opportunities within the health and education sectors. Their team, comprised of scientists and innovators, is dedicated to challenging existing paradigms and improving the health and well-being of individuals throughout their lifespans. DFusion operates from offices in Scotts Valley and Oakland, California.

Backyard Brains specializes in providing accessible neuroscience tools and experiment kits designed for individuals of all ages to explore brain science. The company offers affordable kits that facilitate hands-on learning about electrophysiology, allowing users—from schoolchildren to graduate students—to conduct experiments similar to those performed by professional neuroscientists. Their products enable participants to record and analyze electrical activity from various biological systems, including motor units and the brain itself. By simplifying complex neuroscience concepts, Backyard Brains empowers everyone to engage in the discovery of how the brain communicates, enhancing understanding of its role in senses, memories, and emotions.

Omeros Corporation is a Seattle-based biopharmaceutical company that focuses on discovering, developing, and commercializing small-molecule and protein therapeutics for a range of indications, including inflammation, complement-mediated diseases, and central nervous system disorders. The company is known for its commercial product, OMIDRIA, which is used during cataract surgery in the United States. Omeros has several clinical programs, with its lead candidate, Narsoplimab, in Phase III trials for conditions such as thrombotic microangiopathy and immunoglobulin A nephropathy, as well as Phase II trials for lupus nephritis. Other clinical programs include OMS405 for opioid and nicotine addiction and OMS527 for addiction and compulsive disorders. The company also has a robust pipeline of preclinical programs targeting various disorders, including MASP-3 for paroxysmal nocturnal hemoglobinuria and a GPCR platform aimed at treating a broad range of diseases. Omeros was incorporated in 1994 and remains dedicated to addressing significant unmet medical needs.

Backyard Brains specializes in providing accessible neuroscience tools and experiment kits designed for individuals of all ages to explore brain science. The company offers affordable kits that facilitate hands-on learning about electrophysiology, allowing users—from schoolchildren to graduate students—to conduct experiments similar to those performed by professional neuroscientists. Their products enable participants to record and analyze electrical activity from various biological systems, including motor units and the brain itself. By simplifying complex neuroscience concepts, Backyard Brains empowers everyone to engage in the discovery of how the brain communicates, enhancing understanding of its role in senses, memories, and emotions.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing small molecule drugs for central nervous system disorders. Founded in 1993 and headquartered in San Diego, California, the company is best known for its product NUPLAZID (pimavanserin), which is approved for treating hallucinations and delusions associated with Parkinson’s disease psychosis. Acadia is actively advancing pimavanserin through Phase III clinical trials for dementia-related psychosis and as an adjunctive treatment for schizophrenia, as well as exploring its use for major depressive disorder. The company operates two subsidiaries in Sweden and Denmark and is committed to discovering novel treatments for conditions such as Alzheimer's and schizophrenia, while also seeking to in-license or acquire complementary products. Acadia holds several patent applications related to its proprietary technology, including innovative methods for drug discovery and development.